HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Inclusion Criteria

• •Women and men who are ≥18 years old at signing of informed consent
• •Eastern Cooperative Oncology Group (ECOG) status of 0 to 2
• •Provide written informed consent to participate in the study and for circulating tumor DNA screening
• •Must be able to provide blood sample(s) for HER2 mutation testing
• •Participants with imaging or histologically confirmed, HR-positive, HER2-negative MBC who are presently receiving or have received CDK4/6 inhibitor as a prior therapy in any setting, or participants with imaging or histologically confirmed metastatic cervical cancer
• •At least one measurable lesion, as defined by RECIST v1.1